{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T18:39:49Z","timestamp":1795199989436,"version":"4.10.3"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41584-021-00721-z","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T13:02:52Z","timestamp":1638882172000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Acute exacerbation of interstitial lung disease associated with rheumatic disease"],"prefix":"10.1038","volume":"18","author":[{"given":"Fabrizio","family":"Luppi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-6963","authenticated-orcid":false,"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"721_CR1","doi-asserted-by":"publisher","first-page":"h2072","DOI":"10.1136\/bmj.h2072","volume":"350","author":"A Wallis","year":"2015","unstructured":"Wallis, A. & Spinks, K. The diagnosis and management of interstitial lung diseases. Br. Med. J. 350, h2072\u2013h2072 (2015).","journal-title":"Br. Med. J."},{"key":"721_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis, W. D. et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188, 733\u2013748 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi, L., Collard, H. R. & Jones, M. G. Idiopathic pulmonary fibrosis. Lancet 389, 1941\u20131952 (2017).","journal-title":"Lancet"},{"key":"721_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","volume":"10","author":"AU Wells","year":"2014","unstructured":"Wells, A. U. & Denton, C. P. Interstitial lung disease in connective tissue disease \u2014 mechanisms and management. Nat. Rev. Rheumatol. 10, 728\u2013739 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"721_CR5","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1183\/09031936.00092309","volume":"35","author":"EJ Kim","year":"2010","unstructured":"Kim, E. J. et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur. Respir. J. 35, 1322\u20131328 (2010).","journal-title":"Eur. Respir. J."},{"key":"721_CR6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1183\/09031936.00019210","volume":"37","author":"Y Tsuchiya","year":"2011","unstructured":"Tsuchiya, Y. et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur. Respir. J. 37, 1411\u20131417 (2011).","journal-title":"Eur. Respir. J."},{"key":"721_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","volume":"175","author":"JH Park","year":"2007","unstructured":"Park, J. H. et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am. J. Respir. Crit. Care Med. 175, 705\u2013711 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR8","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.2106012","volume":"165","author":"D Bouros","year":"2002","unstructured":"Bouros, D. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 165, 1581\u20131586 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","volume":"164","author":"WW Douglas","year":"2001","unstructured":"Douglas, W. W. et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am. J. Respir. Crit. Care Med. 164, 1182\u20131185 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR10","doi-asserted-by":"publisher","first-page":"200021","DOI":"10.1183\/16000617.0021-2020","volume":"29","author":"F Luppi","year":"2020","unstructured":"Luppi, F. et al. Lung complications of Sjogren syndrome. Eur. Respir. Rev. 29, 200021 (2020).","journal-title":"Eur. Respir. Rev."},{"key":"721_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/resp.12588","volume":"21","author":"V Cottin","year":"2016","unstructured":"Cottin, V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology 21, 245\u2013258 (2016).","journal-title":"Respirology"},{"key":"721_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley, B., Collard, H. R. & King, T. E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183, 431\u2013440 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y. & Kim, D. S. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 37, 356\u2013363 (2011).","journal-title":"Eur. Respir. J."},{"key":"721_CR14","doi-asserted-by":"publisher","first-page":"1901760","DOI":"10.1183\/13993003.01760-2019","volume":"55","author":"M Kreuter","year":"2020","unstructured":"Kreuter, M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur. Respir. J. 55, 1901760 (2020).","journal-title":"Eur. Respir. J."},{"key":"721_CR15","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/resp.12862","volume":"21","author":"T Arai","year":"2016","unstructured":"Arai, T. et al. Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. Respirology 21, 1431\u20131437 (2016).","journal-title":"Respirology"},{"key":"721_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.chest.2015.12.026","volume":"149","author":"T Moua","year":"2016","unstructured":"Moua, T. et al. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening. Chest 149, 1205\u20131214 (2016).","journal-title":"Chest"},{"key":"721_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000563","volume":"7","author":"J Salonen","year":"2020","unstructured":"Salonen, J., Purokivi, M., Bloigu, R. & Kaarteenaho, R. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir. Res. 7, e000563 (2020).","journal-title":"BMJ Open Respir. Res."},{"key":"721_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/resp.13682","volume":"25","author":"A Suzuki","year":"2020","unstructured":"Suzuki, A. et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology 25, 525\u2013534 (2020).","journal-title":"Respirology"},{"key":"721_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","volume":"103","author":"T Suda","year":"2009","unstructured":"Suda, T. et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir. Med. 103, 846\u2013853 (2009).","journal-title":"Respir. Med."},{"key":"721_CR20","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.rmed.2006.02.002","volume":"100","author":"Y Kondoh","year":"2006","unstructured":"Kondoh, Y. et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir. Med. 100, 1753\u20131759 (2006).","journal-title":"Respir. Med."},{"key":"721_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/crj.13304","volume":"15","author":"K Miyashita","year":"2021","unstructured":"Miyashita, K. et al. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. Clin. Respir. J. 15, 336\u2013344 (2021).","journal-title":"Clin. Respir. J."},{"key":"721_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/01.pas.0000213341.70852.9d","volume":"31","author":"A Churg","year":"2007","unstructured":"Churg, A., Muller, N. L., Silva, C. I. S. & Wright, J. L. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am. J. Surg. Pathol. 31, 277\u2013284 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"721_CR23","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1378\/chest.103.6.1808","volume":"103","author":"Y Kondoh","year":"1993","unstructured":"Kondoh, Y. et al. Acute exacerbation in idiopathic pulmonary fibrosis. Chest 103, 1808\u20131812 (1993).","journal-title":"Chest"},{"key":"721_CR24","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","volume":"176","author":"HR Collard","year":"2007","unstructured":"Collard, H. R. et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176, 636\u2013643 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/MCP.0000000000000405","volume":"23","author":"P Spagnolo","year":"2017","unstructured":"Spagnolo, P. & Wuyts, W. Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med. 23, 411\u2013417 (2017).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"721_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s13665-013-0065-x","volume":"2","author":"KA Johannson","year":"2013","unstructured":"Johannson, K. A. & Collard, H. R. Acute exacerbation of idiopathic pulmonary fibrosis: a proposal. Curr. Respir. Care Rep. 2, 233\u2013240 (2013).","journal-title":"Curr. Respir. Care Rep."},{"key":"721_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard, H. R. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 194, 265\u2013275 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR28","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","volume":"11","author":"A Manfredi","year":"2019","unstructured":"Manfredi, A. et al. Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J. Thorac. Dis. 11, 1621\u20131628 (2019).","journal-title":"J. Thorac. Dis."},{"key":"721_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/MCP.0000000000000073","volume":"20","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson, C. J. & Collard, H. R. Acute exacerbations complicating interstitial lung disease. Curr. Opin. Pulm. Med. 20, 436\u2013441 (2014).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"721_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","volume":"43","author":"C Roubille","year":"2014","unstructured":"Roubille, C. & Haraoui, B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin. Arthritis Rheum. 43, 613\u2013626 (2014).","journal-title":"Semin. Arthritis Rheum."},{"key":"721_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh, J. A. et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386, 258\u2013265 (2015).","journal-title":"Lancet"},{"key":"721_CR32","first-page":"1","volume":"2015","author":"M Kreuter","year":"2015","unstructured":"Kreuter, M. et al. Exploring clinical and epidemiological characteristics of interstitial lung diseases: rationale, aims, and design of a nationwide prospective registry \u2014 the EXCITING-ILD Registry. Biomed. Res. Int. 2015, 1\u20139 (2015).","journal-title":"Biomed. Res. Int."},{"key":"721_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu, G. et al. An Official ATS\/ERS\/JRS\/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 183, 788\u2013824 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00408-020-00383-w","volume":"198","author":"N Jeganathan","year":"2020","unstructured":"Jeganathan, N. & Sathananthan, M. Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 198, 735\u2013759 (2020).","journal-title":"Lung"},{"key":"721_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3899\/jrheum.171315","volume":"46","author":"K Raimundo","year":"2019","unstructured":"Raimundo, K. et al. Rheumatoid arthritis\u2013interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J. Rheumatol. 46, 360\u2013369 (2019).","journal-title":"J. Rheumatol."},{"key":"721_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1183\/13993003.00419-2015","volume":"46","author":"CJ Ryerson","year":"2015","unstructured":"Ryerson, C. J., Cottin, V., Brown, K. K. & Collard, H. R. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur. Respir. J. 46, 512\u2013520 (2015).","journal-title":"Eur. Respir. J."},{"key":"721_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1378\/chest.07-0323","volume":"132","author":"I-N Park","year":"2007","unstructured":"Park, I.-N. et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132, 214\u2013220 (2007).","journal-title":"Chest"},{"key":"721_CR38","doi-asserted-by":"publisher","first-page":"180071","DOI":"10.1183\/16000617.0071-2018","volume":"27","author":"M Kolb","year":"2018","unstructured":"Kolb, M. et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 27, 180071 (2018).","journal-title":"Eur. Respir. Rev."},{"key":"721_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.amjmed.2004.04.031","volume":"118","author":"JPA Ioannidis","year":"2005","unstructured":"Ioannidis, J. P. A. et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. 118, 2\u201310 (2005).","journal-title":"Am. J. Med."},{"key":"721_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1620\/tjem.239.297","volume":"239","author":"F Tomiyama","year":"2016","unstructured":"Tomiyama, F. et al. High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis. Tohoku J. Exp. Med. 239, 297\u2013305 (2016).","journal-title":"Tohoku J. Exp. Med."},{"key":"721_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154441","volume":"11","author":"J-M Peng","year":"2016","unstructured":"Peng, J.-M. et al. Dermatomyositis and polymyositis in the intensive care unit: a single-center retrospective cohort study of 102 patients. PLoS One 11, e0154441 (2016).","journal-title":"PLoS One"},{"key":"721_CR42","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.chest.2021.01.083","volume":"159","author":"H Hozumi","year":"2021","unstructured":"Hozumi, H. et al. Clinical significance of interstitial lung disease and its acute exacerbation in microscopic polyangiitis. Chest 159, 2334\u20132345 (2021).","journal-title":"Chest"},{"key":"721_CR43","doi-asserted-by":"publisher","first-page":"108594","DOI":"10.1016\/j.clim.2020.108594","volume":"220","author":"J Salonen","year":"2020","unstructured":"Salonen, J. et al. Bronchoalveolar lavage differential cell count on prognostic assessment of patients with stable or acute interstitial lung disease: a retrospective real-life study. Clin. Immunol. 220, 108594 (2020).","journal-title":"Clin. Immunol."},{"key":"721_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/toxsci\/kfy309","volume":"168","author":"DL Laskin","year":"2019","unstructured":"Laskin, D. L., Malaviya, R. & Laskin, J. D. Role of macrophages in acute lung injury and chronic fibrosis induced by pulmonary toxicants. Toxicol. Sci. 168, 287\u2013301 (2019).","journal-title":"Toxicol. Sci."},{"key":"721_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116775","volume":"10","author":"JC Schupp","year":"2015","unstructured":"Schupp, J. C. et al. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One 10, e0116775 (2015).","journal-title":"PLoS One"},{"key":"721_CR46","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cells10040897","volume":"10","author":"J-W Lee","year":"2021","unstructured":"Lee, J.-W. et al. The role of macrophages in the development of acute and chronic inflammatory lung diseases. Cells 10, 897 (2021).","journal-title":"Cells"},{"key":"721_CR47","doi-asserted-by":"publisher","first-page":"1900100","DOI":"10.1183\/13993003.00100-2019","volume":"56","author":"CK Probst","year":"2020","unstructured":"Probst, C. K., Montesi, S. B., Medoff, B. D., Shea, B. S. & Knipe, R. S. Vascular permeability in the fibrotic lung. Eur. Respir. J. 56, 1900100 (2020).","journal-title":"Eur. Respir. J."},{"key":"721_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0949-y","volume":"19","author":"K-C Kao","year":"2015","unstructured":"Kao, K.-C. et al. Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy. Crit. Care 19, 228 (2015).","journal-title":"Crit. Care"},{"key":"721_CR49","doi-asserted-by":"publisher","first-page":"L217","DOI":"10.1152\/ajplung.00311.2013","volume":"306","author":"AE Williams","year":"2014","unstructured":"Williams, A. E. & Chambers, R. C. The mercurial nature of neutrophils: still an enigma in ARDS? Am. J. Physiol. Cell. Mol. Physiol. 306, L217\u2013L230 (2014).","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"721_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12931-014-0109-y","volume":"15","author":"K Oda","year":"2014","unstructured":"Oda, K. et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir. Res. 15, 109 (2014).","journal-title":"Respir. Res."},{"key":"721_CR51","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1309\/UVARMDY8FE9FJDKU","volume":"119","author":"AJ Rice","year":"2003","unstructured":"Rice, A. J. et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias: an autopsy study. Am. J. Clin. Pathol. 119, 709\u2013714 (2003).","journal-title":"Am. J. Clin. Pathol."},{"key":"721_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/01.rti.0000213588.52343.13","volume":"22","author":"CIS Silva","year":"2007","unstructured":"Silva, C. I. S. et al. Acute exacerbation of chronic interstitial pneumonia: high-resolution computed tomography and pathologic findings. J. Thorac. Imaging 22, 221\u2013229 (2007).","journal-title":"J. Thorac. Imaging"},{"key":"721_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1378\/chest.08-0703","volume":"136","author":"AL Olson","year":"2009","unstructured":"Olson, A. L., Swigris, J. J., Raghu, G. & Brown, K. K. Seasonal variation. Chest 136, 16\u201322 (2009).","journal-title":"Chest"},{"key":"721_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000329891","volume":"83","author":"V Simon-Blancal","year":"2012","unstructured":"Simon-Blancal, V. et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration 83, 28\u201335 (2012).","journal-title":"Respiration"},{"key":"721_CR55","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.chest.2017.03.033","volume":"152","author":"N Azadeh","year":"2017","unstructured":"Azadeh, N., Limper, A. H., Carmona, E. M. & Ryu, J. H. The role of infection in interstitial lung diseases. Chest 152, 842\u2013852 (2017).","journal-title":"Chest"},{"key":"721_CR56","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network.","year":"2012","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network. et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 366, 1968\u20131977 (2012).","journal-title":"N. Engl. J. Med."},{"key":"721_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12931-017-0511-3","volume":"18","author":"PL Molyneaux","year":"2017","unstructured":"Molyneaux, P. L. et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir. Res. 18, 29 (2017).","journal-title":"Respir. Res."},{"key":"721_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-016-0206-x","volume":"4","author":"JU Scher","year":"2016","unstructured":"Scher, J. U. et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome 4, 60 (2016).","journal-title":"Microbiome"},{"key":"721_CR59","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/art.39783","volume":"68","author":"Y Maeda","year":"2016","unstructured":"Maeda, Y. et al. Dysbiosis contributes to arthritis development via activation of autoreactive t cells in the intestine. Arthritis Rheumatol. 68, 2646\u20132661 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"721_CR60","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/annrheumdis-2018-214514","volume":"78","author":"D Alpizar-Rodriguez","year":"2019","unstructured":"Alpizar-Rodriguez, D. et al. Prevotella copri in individuals at risk for rheumatoid arthritis. Ann. Rheum. Dis. 78, 590\u2013593 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"721_CR61","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1183\/09031936.00050911","volume":"39","author":"JS Lee","year":"2012","unstructured":"Lee, J. S. et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 39, 352\u2013358 (2012).","journal-title":"Eur. Respir. J."},{"key":"721_CR62","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fmed.2017.00176","volume":"4","author":"G Leuschner","year":"2017","unstructured":"Leuschner, G. & Behr, J. Acute exacerbation in interstitial lung disease. Front. Med. 4, 176 (2017).","journal-title":"Front. Med."},{"key":"721_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","volume":"1","author":"JS Lee","year":"2013","unstructured":"Lee, J. S. et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir. Med. 1, 369\u2013376 (2013).","journal-title":"Lancet Respir. Med."},{"key":"721_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"A-M Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold, A.-M. et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann. Rheum. Dis. 80, 219\u2013227 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"721_CR65","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5301\/jsrd.5000214","volume":"1","author":"AB Shreiner","year":"2016","unstructured":"Shreiner, A. B., Murray, C., Denton, C. & Khanna, D. Gastrointestinal manifestations of systemic sclerosis. J. Scleroderma Relat. Disord. 1, 247\u2013256 (2016).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"721_CR66","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1183\/09031936.00122213","volume":"43","author":"KA Johannson","year":"2014","unstructured":"Johannson, K. A. et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur. Respir. J. 43, 1124\u20131131 (2014).","journal-title":"Eur. Respir. J."},{"key":"721_CR67","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12931-019-1128-5","volume":"20","author":"T Miyamura","year":"2019","unstructured":"Miyamura, T. et al. Postoperative acute exacerbation of interstitial pneumonia in pulmonary and non-pulmonary surgery: a retrospective study. Respir. Res. 20, 154 (2019).","journal-title":"Respir. Res."},{"key":"721_CR68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.rmed.2019.02.012","volume":"150","author":"WH Amundson","year":"2019","unstructured":"Amundson, W. H. et al. Acute exacerbation of interstitial lung disease after procedures. Respir. Med. 150, 30\u201337 (2019).","journal-title":"Respir. Med."},{"key":"721_CR69","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.rmed.2011.11.006","volume":"106","author":"K Sakamoto","year":"2012","unstructured":"Sakamoto, K. et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir. Med. 106, 436\u2013442 (2012).","journal-title":"Respir. Med."},{"key":"721_CR70","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/jcm9041082","volume":"9","author":"G Cassone","year":"2020","unstructured":"Cassone, G. et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J. Clin. Med. 9, 1082 (2020).","journal-title":"J. Clin. Med."},{"key":"721_CR71","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel, L. et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 73, 924\u2013939 (2021).","journal-title":"Arthritis Care Res."},{"key":"721_CR72","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis, G. E., Conway, R. & Nikiphorou, E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology 58, 1900\u20131906 (2019).","journal-title":"Rheumatology"},{"key":"721_CR73","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","volume":"60","author":"S Izuka","year":"2020","unstructured":"Izuka, S., Yamashita, H., Iba, A., Takahashi, Y. & Kaneko, H. Acute exacerbation of rheumatoid arthritis\u2013associated interstitial lung disease: clinical features and prognosis. Rheumatology 60, 2348\u20132354 (2020).","journal-title":"Rheumatology"},{"key":"721_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/09059180.00008014","volume":"24","author":"M Shaw","year":"2015","unstructured":"Shaw, M., Collins, B. F., Ho, L. A. & Raghu, G. Rheumatoid arthritis-associated lung disease. Eur. Respir. Rev. 24, 1\u201316 (2015).","journal-title":"Eur. Respir. Rev."},{"key":"721_CR75","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/14712598.2017.1287169","volume":"17","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies. Expert Opin. Biol. Ther. 17, 265\u2013283 (2017).","journal-title":"Expert Opin. Biol. Ther."},{"key":"721_CR76","doi-asserted-by":"publisher","first-page":"2100079","DOI":"10.1183\/13993003.00079-2021","volume":"57","author":"V Cottin","year":"2021","unstructured":"Cottin, V. et al. The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. Eur. Respir. J. 57, 2100079 (2021).","journal-title":"Eur. Respir. J."},{"key":"721_CR77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/S1806-37132014000100012","volume":"40","author":"OM Dias","year":"2014","unstructured":"Dias, O. M. et al. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J. Bras. Pneumol. 40, 77\u201381 (2014).","journal-title":"J. Bras. Pneumol."},{"key":"721_CR78","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard, C. et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann. Rheum. Dis. 76, 1700\u20131706 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"721_CR79","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/1744666X.2021.1905524","volume":"17","author":"A Manfredi","year":"2021","unstructured":"Manfredi, A. et al. Rheumatoid arthritis related interstitial lung disease. Expert Rev. Clin. Immunol. 17, 485\u2013497 (2021).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"721_CR80","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s10067-017-3601-1","volume":"36","author":"A Manfredi","year":"2017","unstructured":"Manfredi, A. et al. Prevalence and characterization of non-sicca onset primary Sj\u00f6gren syndrome with interstitial lung involvement. Clin. Rheumatol. 36, 1261\u20131268 (2017).","journal-title":"Clin. Rheumatol."},{"key":"721_CR81","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/jcm8112013","volume":"8","author":"Cavagna","year":"2019","unstructured":"Cavagna et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J. Clin. Med. 8, 2013 (2019).","journal-title":"J. Clin. Med."},{"key":"721_CR82","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X211032457","volume":"13","author":"M Kuwana","year":"2021","unstructured":"Kuwana, M., Gil-Vila, A. & Selva-O\u2019Callaghan, A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther. Adv. Musculoskelet. Dis. 13, 1759720\u20132110324 (2021).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"721_CR83","first-page":"390","volume":"65","author":"R van der Kamp","year":"2007","unstructured":"van der Kamp, R., Tak, P. P., Jansen, H. M. & Bresser, P. Interstitial lung disease as the first manifestation of systemic sclerosis. Neth. J. Med. 65, 390\u2013394 (2007).","journal-title":"Neth. J. Med."},{"key":"721_CR84","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X211022506","volume":"13","author":"H Furukawa","year":"2021","unstructured":"Furukawa, H. et al. Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 13, 1759720\u20132110225 (2021).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"721_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040465","volume":"11","author":"H Kamiya","year":"2021","unstructured":"Kamiya, H. & Panlaqui, O. M. Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open 11, e040465 (2021).","journal-title":"BMJ Open"},{"key":"721_CR86","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","volume":"41","author":"R Perez-Alvarez","year":"2011","unstructured":"Perez-Alvarez, R. et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin. Arthritis Rheum. 41, 256\u2013264 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"721_CR87","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","volume":"74","author":"KL Winthrop","year":"2015","unstructured":"Winthrop, K. L. et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann. Rheum. Dis. 74, 2107\u20132116 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"721_CR88","doi-asserted-by":"publisher","first-page":"h6819","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai, S. C. & Danoff, S. K. Management of interstitial lung disease associated with connective tissue disease. Br. Med. J. 352, h6819 (2016).","journal-title":"Br. Med. J."},{"key":"721_CR89","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11739-015-1204-x","volume":"10","author":"F Luppi","year":"2015","unstructured":"Luppi, F., Cerri, S., Taddei, S., Ferrara, G. & Cottin, V. Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Intern. Emerg. Med. 10, 401\u2013411 (2015).","journal-title":"Intern. Emerg. Med."},{"key":"721_CR90","doi-asserted-by":"publisher","first-page":"170050","DOI":"10.1183\/16000617.0050-2017","volume":"26","author":"Y Kondoh","year":"2017","unstructured":"Kondoh, Y., Cottin, V. & Brown, K. K. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 26, 170050 (2017).","journal-title":"Eur. Respir. Rev."},{"key":"721_CR91","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1164\/rccm.200709-1365OC","volume":"178","author":"M Akira","year":"2008","unstructured":"Akira, M., Kozuka, T., Yamamoto, S. & Sakatani, M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178, 372\u2013378 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR92","doi-asserted-by":"publisher","first-page":"282","DOI":"10.21037\/atm.2017.06.62","volume":"5","author":"E Rezoagli","year":"2017","unstructured":"Rezoagli, E., Fumagalli, R. & Bellani, G. Definition and epidemiology of acute respiratory distress syndrome. Ann. Transl. Med. 5, 282\u2013282 (2017).","journal-title":"Ann. Transl. Med."},{"key":"721_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2002-4","volume":"22","author":"A Marchioni","year":"2018","unstructured":"Marchioni, A. et al. Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? Crit. Care 22, 80 (2018).","journal-title":"Crit. Care"},{"key":"721_CR94","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/resp.12531","volume":"20","author":"J Jacob","year":"2015","unstructured":"Jacob, J. & Hansell, D. M. HRCT of fibrosing lung disease. Respirology 20, 859\u2013872 (2015).","journal-title":"Respirology"},{"key":"721_CR95","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/14397595.2021.1879346","volume":"31","author":"N Tanaka","year":"2021","unstructured":"Tanaka, N. et al. Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease. Mod. Rheumatol. 31, 1100\u20131106 (2021).","journal-title":"Mod. Rheumatol."},{"key":"721_CR96","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1183\/09031936.00115511","volume":"40","author":"EP Judge","year":"2012","unstructured":"Judge, E. P., Fabre, A., Adamali, H. I. & Egan, J. J. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur. Respir. J. 40, 93\u2013100 (2012).","journal-title":"Eur. Respir. J."},{"key":"721_CR97","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/resp.12909","volume":"22","author":"A Arcadu","year":"2017","unstructured":"Arcadu, A. & Moua, T. Bronchoscopy assessment of acute respiratory failure in interstitial lung disease. Respirology 22, 352\u2013359 (2017).","journal-title":"Respirology"},{"key":"721_CR98","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201508-1632OC","volume":"193","author":"JP Hutchinson","year":"2016","unstructured":"Hutchinson, J. P., Fogarty, A. W., McKeever, T. M. & Hubbard, R. B. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am. J. Respir. Crit. Care Med. 193, 1161\u20131167 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"721_CR99","doi-asserted-by":"publisher","first-page":"180077","DOI":"10.1183\/16000617.0077-2018","volume":"27","author":"AL Olson","year":"2018","unstructured":"Olson, A. L., Gifford, A. H., Inase, N., Fern\u00e1ndez P\u00e9rez, E. R. & Suda, T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur. Respir. Rev. 27, 180077 (2018).","journal-title":"Eur. Respir. Rev."},{"key":"721_CR100","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12890-019-0960-1","volume":"19","author":"M Cao","year":"2019","unstructured":"Cao, M. et al. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. BMC Pulm. Med. 19, 215 (2019).","journal-title":"BMC Pulm. Med."},{"key":"721_CR101","doi-asserted-by":"publisher","first-page":"147997231880947","DOI":"10.1177\/1479972318809476","volume":"16","author":"N Enomoto","year":"2019","unstructured":"Enomoto, N. et al. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chron. Respir. Dis. 16, 147997231880947 (2019).","journal-title":"Chron. Respir. Dis."},{"key":"721_CR102","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003132","volume":"3","author":"H Hozumi","year":"2013","unstructured":"Hozumi, H. et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 3, e003132 (2013).","journal-title":"BMJ Open"},{"key":"721_CR103","first-page":"344","volume":"56","author":"JA Zamora-Legoff","year":"2017","unstructured":"Zamora-Legoff, J. A., Krause, M. L., Crowson, C. S., Ryu, J. H. & Matteson, E. L. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology 56, 344\u2013350 (2017).","journal-title":"Rheumatology"},{"key":"721_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166462","volume":"12","author":"V Cottin","year":"2017","unstructured":"Cottin, V. et al. Burden of idiopathic pulmonary fibrosis progression: a 5-year longitudinal follow-up study. PLoS One 12, e0166462 (2017).","journal-title":"PLoS One"},{"key":"721_CR105","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2152\/jmi.63.294","volume":"63","author":"Y Toyoda","year":"2016","unstructured":"Toyoda, Y. et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J. Med. Investig. 63, 294\u2013299 (2016).","journal-title":"J. Med. Investig."},{"key":"721_CR106","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/1756-185X.13666","volume":"22","author":"P Singh","year":"2019","unstructured":"Singh, P., Thakur, B., Mohapatra, A. K. & Padhan, P. Clinical features and outcome of acute exacerbation in connective tissue disease-associated interstitial lung disease: a single-center study from India. Int. J. Rheum. Dis. 22, 1741\u20131745 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"721_CR107","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmed.2020.00012","volume":"7","author":"J Liang","year":"2020","unstructured":"Liang, J. et al. Acute exacerbation of interstitial lung disease in adult patients with idiopathic inflammatory myopathies: a retrospective case-control study. Front. Med. 7, 12 (2020).","journal-title":"Front. Med."},{"key":"721_CR108","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40744-020-00244-1","volume":"7","author":"H Cao","year":"2020","unstructured":"Cao, H. et al. Predicting survival across acute exacerbation of interstitial lung disease in patients with idiopathic inflammatory myositis: the GAP-ILD model. Rheumatol. Ther. 7, 967\u2013978 (2020).","journal-title":"Rheumatol. Ther."},{"key":"721_CR109","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.2169\/internalmedicine.7875-16","volume":"56","author":"K Koyama","year":"2017","unstructured":"Koyama, K. et al. The activities of daily living after an acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 56, 2837\u20132843 (2017).","journal-title":"Intern. Med."},{"key":"721_CR110","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/resp.13753","volume":"25","author":"E Farrand","year":"2020","unstructured":"Farrand, E., Vittinghoff, E., Ley, B., Butte, A. J. & Collard, H. R. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology 25, 629\u2013635 (2020).","journal-title":"Respirology"},{"key":"721_CR111","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek, M. et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr. Med. Res. Opin. 35, 2015\u20132024 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"721_CR112","doi-asserted-by":"publisher","first-page":"903","DOI":"10.7150\/ijms.4972","volume":"10","author":"J Ding","year":"2013","unstructured":"Ding, J., Chen, Z. & Feng, K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int. J. Med. Sci. 10, 903\u2013907 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"721_CR113","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2169\/internalmedicine.42.565","volume":"42","author":"N Inase","year":"2003","unstructured":"Inase, N. et al. Cyclosporin a followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern. Med. 42, 565\u2013570 (2003).","journal-title":"Intern. Med."},{"key":"721_CR114","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2169\/internalmedicine.44.1144","volume":"44","author":"S Homma","year":"2005","unstructured":"Homma, S. et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern. Med. 44, 1144\u20131150 (2005).","journal-title":"Intern. Med."},{"key":"721_CR115","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2169\/internalmedicine.49.2359","volume":"49","author":"S Sakamoto","year":"2010","unstructured":"Sakamoto, S. et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 49, 109\u2013115 (2010).","journal-title":"Intern. Med."},{"key":"721_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127771","volume":"10","author":"M Donahoe","year":"2015","unstructured":"Donahoe, M. et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS ONE 10, e0127771 (2015).","journal-title":"PLoS ONE"},{"key":"721_CR117","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2169\/internalmedicine.50.4327","volume":"50","author":"N Horita","year":"2011","unstructured":"Horita, N. et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 50, 189\u2013195 (2011).","journal-title":"Intern. Med."},{"key":"721_CR118","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3109\/14397595.2016.1173816","volume":"27","author":"M Ota","year":"2017","unstructured":"Ota, M. et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease. Mod. Rheumatol. 27, 22\u201328 (2017).","journal-title":"Mod. Rheumatol."},{"key":"721_CR119","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.semarthrit.2021.07.008","volume":"51","author":"K Nakamura","year":"2021","unstructured":"Nakamura, K. et al. Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database. Semin. Arthritis Rheum. 51, 977\u2013982 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"721_CR120","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/rheumatology\/ker309","volume":"51","author":"F Pearce","year":"2012","unstructured":"Pearce, F., Johnson, S. R. & Courtney, P. Interstitial lung disease following certolizumab pegol. Rheumatology 51, 578\u2013580 (2012).","journal-title":"Rheumatology"},{"key":"721_CR121","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3109\/14397595.2015.1059008","volume":"27","author":"K Migita","year":"2017","unstructured":"Migita, K. et al. Acute exacerbation of rheumatoid interstitial lung disease during the maintenance therapy with certolizumab pegol. Mod. Rheumatol. 27, 1079\u20131082 (2017).","journal-title":"Mod. Rheumatol."},{"key":"721_CR122","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/rheumatology\/keu142","volume":"53","author":"EM Savage","year":"2014","unstructured":"Savage, E. M., Millar, A. M. & Taggart, A. J. Comment on: a case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology 53, 1154\u20131155 (2014).","journal-title":"Rheumatology"},{"key":"721_CR123","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1007\/s00296-010-1525-z","volume":"32","author":"S Kawashiri","year":"2012","unstructured":"Kawashiri, S., Kawakami, A., Sakamoto, N., Ishimatsu, Y. & Eguchi, K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol. Int. 32, 4023\u20134026 (2012).","journal-title":"Rheumatol. Int."},{"key":"721_CR124","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","volume":"36","author":"M Akiyama","year":"2016","unstructured":"Akiyama, M., Kaneko, Y., Yamaoka, K., Kondo, H. & Takeuchi, T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case\u2013control study. Rheumatol. Int. 36, 881\u2013889 (2016).","journal-title":"Rheumatol. Int."},{"key":"721_CR125","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","volume":"49","author":"T Ding","year":"2010","unstructured":"Ding, T. et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 49, 2217\u20132219 (2010).","journal-title":"Rheumatology"},{"key":"721_CR126","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd, C. R. et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology 58, e3\u2013e42 (2019).","journal-title":"Rheumatology"},{"key":"721_CR127","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/CCM.0000000000004470","volume":"48","author":"MJ Martin","year":"2020","unstructured":"Martin, M. J. & Moua, T. Mechanical ventilation and predictors of in-hospital mortality in fibrotic interstitial lung disease with acute respiratory failure. Crit. Care Med. 48, 993\u20131000 (2020).","journal-title":"Crit. Care Med."},{"key":"721_CR128","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","volume":"5","author":"M Kreuter","year":"2017","unstructured":"Kreuter, M. et al. Palliative care in interstitial lung disease: living well. Lancet Respir. Med. 5, 968\u2013980 (2017).","journal-title":"Lancet Respir. Med."},{"key":"721_CR129","doi-asserted-by":"publisher","first-page":"30629","DOI":"10.3402\/ecrj.v3.30629","volume":"3","author":"C Kohberg","year":"2016","unstructured":"Kohberg, C., Andersen, C. U. & Bendstrup, E. Opioids: an unexplored option for treatment of dyspnea in IPF. Eur. Clin. Respir. J. 3, 30629 (2016).","journal-title":"Eur. Clin. Respir. J."},{"key":"721_CR130","first-page":"CD007354","volume":"10","author":"ST Simon","year":"2016","unstructured":"Simon, S. T. et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst. Rev. 10, CD007354 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"721_CR131","doi-asserted-by":"publisher","first-page":"1801278","DOI":"10.1183\/13993003.01278-2018","volume":"52","author":"S Bajwah","year":"2018","unstructured":"Bajwah, S. et al. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur. Respir. J. 52, 1801278 (2018).","journal-title":"Eur. Respir. J."},{"key":"721_CR132","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12931-020-01452-7","volume":"21","author":"S Kronborg-White","year":"2020","unstructured":"Kronborg-White, S., Andersen, C. U., Kohberg, C., Hilberg, O. & Bendstrup, E. Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease \u2014 a randomised placebo-controlled trial. Respir. Res. 21, 195 (2020).","journal-title":"Respir. Res."},{"key":"721_CR133","doi-asserted-by":"publisher","first-page":"170076","DOI":"10.1183\/16000617.0076-2017","volume":"27","author":"G Ferrara","year":"2018","unstructured":"Ferrara, G. et al. Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. Eur. Respir. Rev. 27, 170076 (2018).","journal-title":"Eur. Respir. Rev."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00721-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00721-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00721-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T05:19:37Z","timestamp":1676006377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00721-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1038\/s41584-021-00721-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"10 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}